The FDA looks at Carvykti and Abecma and agrees they can both be Bob Beamon long jumpers!
A couple of weeks back I wrote on the good fortune of Carvykti in Europe. Its marketing authorisation had been approved […]
Read MoreAuthor: claireoliverharwood
GSK’s PD-1 drug Jemperli performs so well in the endometrial cancer RUBY study it might even get a chance to become the backbone treatment!
A couple of days ago (16th March 2024), GSK posted absolutely excellent data on their PD-1 drug Jemperli (dostarlimab) at a […]
Read MoreShifting the paradigm in the management of early prostate cancer
Outcomes from active surveillance have clearly shown that it is the optimal method of managing many early prostate cancers. Yet, […]
Read MoreThe phase 2 LYSA study of prednisone, vinblastine, doxorubicin, and bendamustine for untreated Hodgkin lymphoma in older patients
Older patients with classical Hodgkin lymphoma (cHL) require more effective and less toxic therapies than younger patients. In this multicenter, […]
Read MoreArtificial Intelligence Individualized Risk Classifier in Multiple Myeloma
Advancements in comprehending the biogenesis, dependencies, and mutational landscape of multiple myeloma dramatically expanded over the past two decades. This […]
Read MoreLoss of Myo19 increases metastasis by enhancing microenvironmental ROS gradient and chemotaxis
Tumor metastasis involves cells migrating directionally in response to external chemical signals. Reactive oxygen species (ROS) in the form of […]
Read MorePrognostic Impact of Prostate-Specific Antigen at 6 Months After Radiotherapy in Localized Prostate Cancer: An Individual Patient Data Analysis of Randomized Trials
We sought to evaluate the prognostic impact of prostate-specific antigen (PSA) at 6 months after completion of radiotherapy (RT) in […]
Read MoreExpect more “Shots on Goal” with bispecifics
I said in my blog yesterday that we should rightly be excited about Pfizer’s bet on bispecifics and a week on […]
Read MoreTreatment patterns and outcomes in metastatic castration-resistant prostate cancer patients with and without somatic or germline alterations in homologous recombination repair genes
Although germline BRCA mutations have been associated with adverse outcomes in prostate cancer (PC), understanding of the association between somatic/germline alterations in […]
Read MoreEarly Detection of Disease Progression in Metastatic Cancers: Could CTCs Improve RECIST Criteria?
Early detection of disease progression is a crucial issue in the management of cancer patients, especially in metastatic settings. Currently, […]
Read More